急性脑梗死TOAST各分型纤维蛋白原水平的变化及松龄血脉康的干预研究  

Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang

作　　者：杨德刚[1] 卢年芳[1] 刘筱洁[1] 刘刚[1] 徐耀[1] 黄金忠[1] 陈应柱[1] 

机构地区：[1]扬州大学临床医学院苏北人民医院,江苏扬州225001

出　　处：《中国中药杂志》2010年第10期1339-1341,共3页China Journal of Chinese Materia Medica

摘　　要：目的:探讨急性脑梗死TOAST各分型纤维蛋白原水平(Fbg)的变化及松龄血脉康的干预效果。方法:将160例住院急性脑梗死患者随机分为治疗组和对照组,其中治疗组(松龄血脉康胶囊+疏血通注射液+拜阿司匹林组)85例,对照组(疏血通注射液+拜阿司匹林组)75例,检测各亚型的Fbg水平。结果:大动脉粥样硬化脑梗死(LAA)、心源性脑栓塞(CE)、小动脉闭塞脑梗死(SAO)血清Fbg与其他明确病因的脑梗死(OC)比较有统计学意义(P<0.05),LAA、CE、SAO与不明病因性脑梗死(UE)比较有统计学意义(P<0.05),LAA与SAO比较有统计学意义(P<0.05)。治疗组TOAST各型中LAA,CE,SAO治疗前后比较有显著差异(P<0.05);15 d后治疗组LAA,CE,SAO 3型与对照组比较有显著性差异(P<0.05)。结论:Fbg在大动脉粥样硬化型梗死、心源性脑栓塞、小动脉闭塞型脑梗死的发生发展中都发挥着重要作用。松龄血脉康可显著降低脑梗死患者的Fbg水平,可作为脑梗死的有效辅助治疗药物。Objective： To investigate the changes of plasma fibrinogen level among acute ischemic stroke（ACI） subtypes according to Trial of Org10172 in Acute Stroke Treatment（TOAST） criteria and effects of Songling Xuemaikang.Method： The 160 patients with acute iachemic stroke were divided into two groups randomly： treatment group 85 cases（Songling Xuemaikang ＋ Shuxuetong＋ Aspirin enterie ccoated tablets）,control group 75 cases（Shuxuetong ＋ Aspirin enterie ccoated tablets）.The plasma fibrinogen was detected before and after treatment.Result： Compared with OC subtype,Fbg was higher in LAA,CE and SAO subtypes（P0.05）.Compared with UE subtype,Fbg was higher in LAA,CE and SAO subtypes（P0.05）.There was a significantly difference between LAA and SAO（P0.05）.In LAA,SAO,CE of treatment group,the Fbg level were lowered significantly at the 15th day compared with pretherapy（P0.05）.There was a significantly difference of Fbg between treatment group and control group In LAA,SAO and CE subtypes at the 15th day（P0.05）.Conclusion： Fbg produces a marked effect at the pathomechanism of LAA,SAO and CE subtypes.Songling Xuemaikang can depress the plasma fibrinogen level of ACI,and be an effective adjunctive therapy on ACI.

关 键 词：急性脑梗死 TOAST分型 纤维蛋白原 松龄血脉康 

分 类 号：R743.33[医药卫生—神经病学与精神病学]